CarMax, Inc (KMX) Stock Price Today
Aura AI Summary
Key Stats
- $7.57BMarket Cap
- 2,304,625Volume
- Consumer CyclicalSector
- $64.2252W High
- $30.8852W Low
- 49 DaysTypical Hold Time
- $25.27BEnterprise Value
- -Div Yield
- -Trading Activity
Track CarMax, Inc (KMX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CarMax, Inc has traded between a low of $30.88 and a high of $64.22, highlighting its annual price range. Buy and sell CarMax, Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Most Recent News
Berkshire Hathaway earned $479M dividends from $1.3B American Express stake last year.
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026
JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.